{
  "id": "everyday#risk_safety_07facab6",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "Medication-Induced Movement Disorders 349 Neuroleptic malignant syndrome also must be distinguished from similar syndromes resulting from the use of other substances or medi- cations, such as serotonin syndrome; parkinsonian hyperthermia syn- drome following abrupt discontinuation of dopamine agonists; alcohol or sedative withdrawal; malignant hyperthermia occurring during anesthesia; hyperthermia associated with abuse of stimulants and hallu- cinogens; and atropine poisoning from anticholinergics. In rare instances, individuals with schizophrenia or a mood disor- der may present with malignant catatonia, which may be indistin- guishable from neuroleptic malignant syndrome. Some investigators consider neuroleptic malignant syndrome to be a drug-induced form of malignant catatonia. Medication-Induced Acute Dystonia 333.72 (G24.02) Medication-Induced Acute Dystonia Abnormal and prolonged contraction of the muscles of the eyes (oc- ulogyric crisis), head, neck (torticollis or retrocollis), limbs, or trunk developing within a few days of starting or raising the dosage of a medication (such as a neuroleptic) or after reducing the dosage of a medication used to treat extrapyramidal symptoms. Medication-Induced Acute Akathisia 333.99 (G25.71) Medication-Induced Acute Akathisia Subjective complaints of restlessness, often accompanied by ob- served excessive movements (e.g., fidgety movements of the legs, rocking from foot to foot, pacing, inability to sit or stand still), devel- oping within a few weeks of starting or raising the dosage of a med- ication (such as a neuroleptic) or after reducing the dosage of a medication used to treat extrapyramidal symptoms. Tardive Dyskinesia 333.85 (G24.01) Tardive Dyskinesia Involuntary athetoid or choreiform movements (lasting at least a few weeks) generally of the tongue, lower face and jaw, and extremities",
  "gloss_vi": "Medication-induced movement disorders 349 neuroleptic malignant syndrome also must be distinguished from similar syndromes resulting from the use of other substances or medi- cations, such as serotonin syndrome; parkinso...",
  "source": "Everyday Essentials",
  "url": "",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "screening_cues"
    ],
    "life_topics": [],
    "advice_section": [
      "work_habits"
    ],
    "audience": [],
    "risk_band": "high"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn Medication-Induced Movement Disorders 349 Neuroleptic malignant syndrome also must be distinguished from similar syndromes resulting from the use of other substances or medi- cations, such as serotonin syndrome; parkinsonian hyperthermia syn- drome following abrupt discontinuation of dopamine agonists; alcohol or sedative withdrawal; malignant hyperthermia occurring during anesthesia; hyperthermia associated with abuse of stimulants and hallu- cinogens; and atropine poisoning from anticholinergics. In rare instances, individuals with schizophrenia or a mood disor- der may present with malignant catatonia, which may be indistin- guishable from neuroleptic malignant syndrome. Some investigators consider neuroleptic malignant syndrome to be a drug-induced form of malignant catatonia. Medication-Induced Acute Dystonia 333.72 (G24.02) Medication-Induced Acute Dystonia Abnormal and prolonged contraction of the muscles of the eyes (oc- ulogyric crisis), head, neck (torticollis or retrocollis), limbs, or trunk developing within a few days of starting or raising the dosage of a medication (such as a neuroleptic) or after reducing the dosage of a medication used to treat extrapyramidal symptoms. Medication-Induced Acute Akathisia 333.99 (G25.71) Medication-Induced Acute Akathisia Subjective complaints of restlessness, often accompanied by ob- served excessive movements (e.g., fidgety movements of the legs, rocking from foot to foot, pacing, inability to sit or stand still), devel- oping within a few weeks of starting or raising the dosage of a med- ication (such as a neuroleptic) or after reducing the dosage of a medication used to treat extrapyramidal symptoms. Tardive Dyskinesia 333.85 (G24.01) Tardive Dyskinesia Involuntary athetoid or choreiform movements (lasting at least a few weeks) generally of the tongue, lower face and jaw, and extremities Medication-induced movement disorders 349 neuroleptic malignant syndrome also must be distinguished from similar syndromes resulting from the use of other substances or medi- cations, such as serotonin syndrome; parkinso..."
}